Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Author Correction: Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice.

Autor: Ranjbarvaziri S; Tenaya Therapeutics, South San Francisco, CA, USA., Zeng A; Tenaya Therapeutics, South San Francisco, CA, USA., Wu I; Tenaya Therapeutics, South San Francisco, CA, USA., Greer-Short A; Tenaya Therapeutics, South San Francisco, CA, USA., Farshidfar F; Tenaya Therapeutics, South San Francisco, CA, USA., Budan A; Tenaya Therapeutics, South San Francisco, CA, USA., Xu E; Tenaya Therapeutics, South San Francisco, CA, USA., Shenwai R; Tenaya Therapeutics, South San Francisco, CA, USA., Kozubov M; Tenaya Therapeutics, South San Francisco, CA, USA., Li C; Tenaya Therapeutics, South San Francisco, CA, USA., Van Pell M; Tenaya Therapeutics, South San Francisco, CA, USA., Grafton F; Tenaya Therapeutics, South San Francisco, CA, USA., MacKay CE; Tenaya Therapeutics, South San Francisco, CA, USA., Song X; Tenaya Therapeutics, South San Francisco, CA, USA., Priest JR; Tenaya Therapeutics, South San Francisco, CA, USA., Argast G; Tenaya Therapeutics, South San Francisco, CA, USA., Mandegar MA; Tenaya Therapeutics, South San Francisco, CA, USA., Hoey T; Tenaya Therapeutics, South San Francisco, CA, USA., Yang J; Tenaya Therapeutics, South San Francisco, CA, USA. flairjinyang@gmail.com.

Publikováno v: Nature communications [Nat Commun] 2024 Oct 09; Vol. 15 (1), pp. 8749. Date of Electronic Publication: 2024 Oct 09.